Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Chief Financial Officer | March 01, 2025 | March 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date March 01, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2035-02-28 | Direct | 109,309 |
Reported balance
After 2025-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-01 · Grant · Acquired 109,309 · Balance 109,309 F1: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2025 Filed Mar 4, 2025 22:28 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 109,309 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000905148-25-000838 · form4.xml · derivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,309 Underlying: Common Stock · 109,309 shares Expires 2035-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:55 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 434 | $5.42 | $2,352.28 |
DisclosureSEC source: 0000905148-25-000728 · form4.xml · nonDerivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,088 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:30 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 368 | $7.92 | $2,914.56 |
DisclosureSEC source: 0000905148-24-003226 · form4.xml · nonDerivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,522 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:51 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 368 | $7.02 | $2,583.36 |
DisclosureSEC source: 0000905148-24-002280 · form4.xml · nonDerivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,890 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:00 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 368 | $8.36 | $3,076.48 |
DisclosureSEC source: 0000905148-24-001489 · form4.xml · nonDerivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,258 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Nov 27, 2024 23:10 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 90,090 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000905148-24-003293 · form4.xml · derivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,090 Underlying: Common Stock · 90,090 shares Expires 2034-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:12 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 434 | $3.40 | $1,475.60 |
DisclosureSEC source: 0000905148-24-000763 · form4.xml · nonDerivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,626 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2023 Filed Nov 17, 2023 00:42 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 1,470 | $5.08 | $7,467.60 |
DisclosureSEC source: 0000905148-23-001475 · form4.xml · nonDerivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,060 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:21 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $3.63 | $0.00 |
DisclosureSEC source: 0001140361-23-030544 · form4.xml · derivative · entry 2 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,119 Underlying: Common Stock · 9,500 shares Expires 2032-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on April 20, 2023, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:21 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Exercise / conversionCommon Stock | 9,500 | $3.63 | $34,485.00 |
DisclosureSEC source: 0001140361-23-030544 · form4.xml · nonDerivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:13 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 60,090 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001209191-22-057398 · doc4.xml · derivative · entry 2 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,090 Underlying: Common Stock · 60,090 shares Expires 2032-11-13 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:13 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 20,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057398 · doc4.xml · nonDerivative · entry 1 Holm-Jorgensen Rasmus · CIK 0001950496 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,030 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, twenty-five percent (25%) of the RSUs shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.